Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06012669 · ClinicalTrials.gov registry record · NA
Effects of Lactoferrin at Two Doses vs. Active Control on Markers of Immune Function
A NA study, sponsored by Midwest Center for Metabolic and Cardiovascular Research.
- Completed
- Registry status
- NA
- Development phase
- 66
- Enrollment target
NCT06012669: Completed NA study, sponsored by Midwest Center for Metabolic and Cardiovascular Research.
NCT06012669 is a NA study that has completed, run by Midwest Center for Metabolic and Cardiovascular Research. The registered enrollment target is 66 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06012669, a NA study, has completed, sponsored by Midwest Center for Metabolic and Cardiovascular Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the impact of 28-day supplementation with high-dose human recombinant lactoferrin, low-dose human recombinant lactoferrin, and an active control product formulated with bovine lactoferrin on indicators of immunity in healthy males and females.
Primary Outcome
Change from baseline in anti-lactoferrin antibodies
Interventions
- DIETARY_SUPPLEMENT High dose Human Lactoferrin
- DIETARY_SUPPLEMENT Low dose Human Lactoferrin
- DIETARY_SUPPLEMENT Active Control Bovine Lactoferrin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2023-09-06 |
| Est. Completion | 2023-12-27 |
| Phase | NA |
What the finished NCT06012669 record still lists
NCT06012669 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 3 interventions - of which High dose Human Lactoferrin is the first listed.
NCT06012669 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06012669 about?
NCT06012669 is a clinical study titled "Effects of Lactoferrin at Two Doses vs. Active Control on Markers of Immune Function". The purpose of this study is to evaluate the impact of 28-day supplementation with high-dose human recombinant lactoferrin, low-dose human recombinant lactoferrin, and an active control product formulated with bovine lactoferrin on indicators of immunity in healthy males and females.
What is the current status of trial NCT06012669?
This trial is currently completed. It is a NA study. The enrollment target is 66 participants. The study started on 2023-09-06. Estimated completion is 2023-12-27.
What interventions are being tested in trial NCT06012669?
The interventions under investigation include: High dose Human Lactoferrin (DIETARY_SUPPLEMENT), Low dose Human Lactoferrin (DIETARY_SUPPLEMENT), Active Control Bovine Lactoferrin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06012669?
This trial is sponsored by Midwest Center for Metabolic and Cardiovascular Research, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06012669's enrollment target sits among peer trials
66 1139th of 2000 higher than 857 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI